Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from ...

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from researchers at the Hackensack Meridian Center for Discovery and Innovation ...

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and bispecifics will bring another shift. The shift toward subcutaneous ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that ...

BostonGene, the developer of the leading AI model for tumor and immune biology, today announced a strategic research partnership with Kyoto University, a research institution known for its ...

Prostate tumors can vanish from the immune system’s radar. Now, scientists have found a way to strip away that disguise by changing the length of a single RNA molecule.

Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation macrophage-directed immunotherapies for cancer, today announced a peer-reviewed publication in Clinical Cancer ...

Explore how immune cell populations are reshaped within the tumor microenvironment and how in vivo models can guide the ...

Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" ...

Pelareorep FDA Fast Track designation opens a registrational path for a viral immunotherapy targeting advanced anal cancer ...

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease ...

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.